Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. (Q53816764)

20 May 2018

title

Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. (English)

1 reference

20 May 2018

Mycobacterium tuberculosis

main subject

0 references

1 reference

Lin Zou

1

1 reference

20 May 2018

Min Liu

2

1 reference

20 May 2018

Yufeng Wang

3

1 reference

20 May 2018

Jie Lu

4

1 reference

20 May 2018

Yu Pang

5

1 reference

20 May 2018

publication date

5 September 2015

1 reference

20 May 2018

published in

Tuberculosis

1 reference

20 May 2018

volume

95

1 reference

20 May 2018

issue

6

1 reference

20 May 2018

page(s)

839-842

1 reference

20 May 2018

Global epidemiology of tuberculosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Linezolid in the treatment of extensively drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

National survey of drug-resistant tuberculosis in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Resistance to linezolid caused by modifications at its binding site on the ribosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.07.003

10.1016/J.TUBE.2015.07.003

7 January 2021

Identifiers

DOI

1 reference

20 May 2018

1 reference

20 May 2018